This refers to the report about the low-calorie sweetener stevia in “Coca-Cola applies to food safety body on new sweetener” (November 9). As a nutrition professional with the Calorie Control Council, I found the comments describing the low-calorie sweeteners acesulfame K, sucralose (brand name Splenda), and aspartame as “synthesised chemicals that are carcinogenic” not only inaccurate but false, and not based on sound science.
Low-calorie sweeteners are among the most rigorously tested ingredients in the food supply. The safety of sucratose, aspartame and acesulfame K has been confirmed by leading medical, scientific and regulatory authorities around the world, including the US Food and Drug Administration, the Joint Food and Agriculture Organisation/ World Health Organisation Expert Committee on Food Additives and the European Commission’s Scientific Committee for Foods. The safety of sucralose is documented by one of the most extensive and thorough safety testing programmes on a new food additive. There is no reason to believe that sucralose could have any negative health impact, including cancer, as most of it is not absorbed or accumulated in the body. Moreover, studies show that low-calorie sweeteners, including sucralose, can be useful for managing calories as well as blood glucose, which are common concerns.
More than three decades of research and 200 studies support the safety of aspartame. Importantly, aspartame never enters the bloodstream and thus there can be no physiological damage. More than 90 studies have demonstrated the safety of acesulfame K on nine separate occasions in broadening its approval. Acesulfame K has been used in Europe since 1983 and in the US since 1988, with no known documented adverse health effects.
Joan Patton, Atlanta
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
